Here's What You May Have Missed About AstraZeneca PLC(AZN)

By Kim Brooks • Tuesday, December 12 12:06 • Permanent Link

More and more people are talking about AstraZeneca PLC over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $63.92? Only time will tell. The information below will give you a basic idea of what this investment may entail:

AstraZeneca PLC has moved -8.7% over the last year, and the S&P 500 logged a change of 15.0%
AZN has an average analyst rating of buy and is -22.81% away from its mean target price of $82.81 per share
Its trailing earnings per share (EPS) is $1.89
AstraZeneca PLC has a trailing 12 month Price to Earnings (P/E) ratio of 33.8 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $4.3 and its forward P/E ratio is 14.9
The company has a Price to Book (P/B) ratio of 2.66 in contrast to the S&P 500's average ratio of 2.95
AstraZeneca PLC is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
AZN has reported YOY quarterly earnings growth of -16.2% and gross profit margins of 0.9%
The company has a free cash flow of $12.67 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.